Table 4.

Prevalence of cancer stratified by antibodies against individual Th/To subunits. In general, antibodies against Th/To subunit(s) appear to have a protective effect against cancer, with shorter-interval cancers being the most protected. Some analyses are limited by too few cancers in the anti-Th/To+ group, preventing conclusions about the relationship between the number of anti-Th/To specificities (epitope spreading) and cancer risk. This analysis excludes non-melanotic skin cancers; other analyses treating NMSC as cancers or NMSC in the cancer-negative group generate similar findings.

	Any Component			P0P1			RPP25			RPP30			RPP40
	POS n(%)	NEG n(%)	p-value	POS n(%)	NEG n(%)	p-value	POS n m	NEG n(%)	p-value	POS n(%)	NEG n m	p-value	POS n(%)	NEG n(%)	p-value
Cancer (ever)	23 (34)	286(39)	0.514	22(34)	287(39)	0.506	12(29)	297(39)	0.196	20(42)	289 (38)	0.648	23(37)	286(39)	0.892
Cancer (within 5 years)	4(8)	110(20)	0.055	4(8.5)	110(20)	0.078	1(3)	113(20)	0.018	4(13)	110(19)	0.486	4(9)	110(19)	0.109
Cancer (within 3 years)	2(2)	83(16)	0.048	2(4)	83(16)	0.047	1(3)	84(15)	0.069	2(7)	83 (15)	0.290	2(5)	83(15)	0.069
Cancer (within 2 years)	0(0)	58(11)	0.009	0(0)	58(11)	0.016	0(0)	58(11)	0.061	0(0)	58(11)	0.061	0(0)	58(11)	0.025